The endometrial cancer cell lines HEC1A (type I, PIK3CA G1049R mutated), HEC1B (type I, PIK3CA G1049R mutated), and AN3CA (type II, PTEN loss) were obtained from the American Type Culture Collection (Manassas, VA, USA). HEC1A and HEC1A-TR cells were maintained in Dulbecco’s Modified Eagle Medium (catalog no. LM001-05; Welgene Inc., Deagu, Korea), whereas AN3CA, HEC1B, and HEC1B-TR were maintained in Minimum Essential Medium (catalog no. LM007-07; Welgene Inc., Deagu, Korea). Briefly, 10% heat-inactivated FBS (catalog no. S001-01; Welgene Inc., Deagu, Korea) and 1% 100 × P/S solution (catalog no. LS202-02; Welgene Inc.) was added to all basal media.
Jeong Y.G., Katuwal N.B., Kang M.S., Ghosh M., Hong S.D., Park S.M., Kim S.G., Kim T.H, & Moon Y.W. (2023). Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer. Cancers, 15(19), 4887.
+ Open protocol